Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zavegepant Intranasal for Acute Treatment of Migraine in Asian Adults
NCT05989048Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of zavegepant in migraine, sponsored by Pfizer. Started Nov 2023; status: completed.
02
Drugs
zavegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05989048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05989048.